Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (06) : 581-584     DOI: 10.3971/j.issn.1000-8578.2022.21.1231
|
Transcriptome Analysis of Inhibitory Effect of Astaxanthin Against HepG2 Cell Lines
XU Huan, WANG Guangli, LI Tingming, WANG Wei, DONG Dandan
Department of Infectious Diseases, Wuhan No.7 Hospital, Wuhan 430071, China
Download: PDF(5841 KB)   ( 29 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To investigate the gene expression differences of hepatocellular carcinoma (HCC) cells treated with astaxanthin and to analyze its biological information. Methods After treated with astaxanthin, the total RNA of HCC cells was extracted with TRIzol reagent. Illumina TruseqTM RNA sample Prep Kit was used for RNA-seq library construction and sequencing. We analyzed the differentially-expressed genes and function enrichments. Results Transcriptomic analysis showed that there were 39 642 566 and 497 1 55 920 reads in the control group and treatment group, respectively; the proportion of clean reads obtained by filtration were 94.89% and 93.56%, respectively. A total of 77 344 transcripts were detected, with 4 997 genes with significant differences in expression, among which 1 564 genes were up-regulated and 3 433 genes were down-regulated. Conclusion Astaxanthin may participate in several biological processes and signaling pathways of tumors. Significant repression of translation process by astaxanthin may result in the growth inhibition of HCC.
Keywords Astaxanthin      Hepatocellular carcinoma      RNA-seq     
ZTFLH:  R735.7  
Issue Date: 16 June 2022
 Cite this article:   
XU Huan,WANG Guangli,LI Tingming, et al. Transcriptome Analysis of Inhibitory Effect of Astaxanthin Against HepG2 Cell Lines[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 581-584.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.1231
http://www.zlfzyj.com/EN/Y2022/V49/I06/581
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
XU Huan
WANG Guangli
LI Tingming
WANG Wei
DONG Dandan
[1] 刘乐恒, 赵艳, 张茜,等. 肠道菌群紊乱与肝癌的研究进展[J]. 肿
瘤防治研究, 2019, 46(12): 11 36-11 40. [Liu LH, Zhao Y, Zhang
Q, et al. Progress of intestinal flora disorder and hepatocellular
cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2019, 46(12): 11 36-11 40.]
[2] Oslan SNH. Tan JS, Oslan SN, et al. Haematococcus pluvialis
as a potential source of astaxanthin with diverse applications
in industrial sectors: current research and future directions[J].
Molecules, 2021, 26(21): 6470.
[3] Villaró M, Ciardi A, Morillas-Espa?a A, et al. Microalgae Derived
Astaxanthin: Research and Consumer Trends and Industrial Use
as Food[J]. Foods, 2021, 10(10): 2303.
[4] 曹秀明, 杨贵群, 杨菲菲. 虾青素对过氧化氢所致细胞线粒体氧
化损伤及生存能力下降的保护作用[J]. 中国海洋药物, 2010,
29(5): 26-32. [Cao XM, Yang GQ, Yang FF. Protective effect of
astaxanthin on oxidative mitochondrial damage and decreased
viability in cells caused by hydrogen peroxide[J]. Zhongguo Hai
Yang Yao Wu, 2010, 29(5): 26-32.]
[5] 刁翠茹, 王静, 闫勇, 等. 虾青素对高脂HepG2细胞及高脂膳食
饲喂C57BL/6J小鼠血脂代谢的影响[J]. 食品科学, 2020, 41(17):
139-144. [Diao CR, Wang J, Yan Y, et al. Effect of astaxanthin on
lipid metabolism in HepG2 cells and in C57BL/6J mice fed with
high-fat diet[J]. Shi Pin Ke Xue, 2020, 41(17): 139-144.]
[6] Nagaraj S, Rajaram MG, Arulmurugan P, et al. Antiproliferative
potential of astaxanthin-rich alga Haematococcus pluvialis
Flotow on human hepatic cancer (HepG2) cell line[J]. Biomed
Prev Nutrition, 2012, 2(3): 149-153.
[7] Silva W, Fabián AH, Kelly S, et al. Transcriptome Analysis Using
RNA-seq and scRNA-seq[M]//Passos GA Transcriptomics in
Health and Disease. Switzerland: Springer, Cham, 2022: 73-107.
[8] Caron A, Baraboi ED, Laplante M, et al. DEP domain-containing
mTOR-interacting protein in the rat brain: Distribution of
expr‍ession and potential implication[J]. J Comp Neurol, 2015,
523(1): 93-107.
[9] Peterson JD, Umayam LA, Dickinson T, et al. The Comprehensive
Microbial Resource[J]. Nucleic Acids Res, 2001, 29(1): 123-125.
[10] Szabo L, Morey R, Palpant NJ, et al. Statistically based splicing
detection reveals neural enrichment and tissue-specific induction
of circular RNA during human fetal development[J]. Genome
Biol, 2015, 16(4): 126.
[11 ] 宋晓冬, 王美蓉, 张瑾锦, 等. 虾青素对大鼠肝癌CBRH-7919
细胞骨架和nm23蛋白的影响[J]. 滨州医学院学报, 2010,
33(5): 321-324. [Song XD, Wang MR, Zhang JJ, et al. Effect of
astaxanthin on cytoskeleton and nm23 protein in rat hepatocellular
carcinoma CBRH-7919 cells[J]. Binzhou Yi Xue Yuan Xue Bao,
2010, 33(5): 321-324.]
[12] 周雅婷, 罗志强, 张彬彬, 等. 基于转录组学的芍药内酯苷抗肝
癌的作用机制研究[J]. 中南药学, 2021, 1 9(6): 1 074-1079. [Zhou
YT, Luo ZQ, Zhang BB, et al. Mechanism of albiflorin against
hepatocellular carcinoma based on transcriptomics[J]. Zhong Nan
Yao Xue, 2021, 19(6): 1074-1079.]
[13] 申文豪, 杨颂, 姜敏, 等. 三七总皂苷诱导下的肝癌细胞HepG2
细胞转录组测序分析[J]. 泰州职业技术学院学报, 2020, 20(6):
61-63. [Shen WH, Yang S, Jiang M, et al. Transcriptometric
analysis of HepG2 cells induced by Panax Notoginseng
Saponin[J]. Taizhou Zhi Ye Ji Shu Xue Yuan Xue Bao, 2020,
20(6): 61-63.]
[14] 张满桥, 文娅, 陆菁潇, 等. α-硫辛酸作用肝癌细胞的转录组分
析及验证[J]. 基因组学与应用生物学, 2020, 39(8): 3672-3680.
[Zhang MQ, Wen Y, Lu JX, et al. Transcriptome analysis and
validation of hepatoma cells treated with alpha-lipoic acid[J].
Ji Yin Zu Xue Yu Ying Yong Sheng Wu Xue, 2020, 39(8):
3672-3680.]
[15] Semenov AL, Gubareva EA, Ermakova, ED, et al. Astaxantin
and Isoflavones Inhibit Benign Prostatic Hyperplasia in Rats by
Reducing Oxidative Stress and Normalizing Ca/Mg Balance[J].
Plants (Basel), 2021, 10(12): 2735.
[16] Kim SH, Hyeyoung Kim. Inhibitory Effect of Astaxanthin on
Gene Expression Changes in Helicobacter pylori-Infected Human
Gastric Epithelial Cells[J]. Nutrients, 2021, 13(12): 4281.
[17] Ramamoorthy K, Raghunandhakumar S, Anand RS, et al.
Anticancer effects and lysosomal acidification in A549 cells by
Astaxanthin from Haematococcus lacustris[J]. Bioinformation,
2020, 16(11 ): 965-973.
Related articles from Frontiers Journals
[1] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[2] ZHOU Zhipeng, YANG Mingzhu, CAI Mingqin, XUE Juandi, LYU Xiaoyun. Mechanism of Astragaloside IV on HepG2 Cells Based on Molecular Dynamics Simulation and Experimental Evaluation[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 655-661.
[3] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[4] ZHOU Shi. Progress in Locoregional Interventional Therapy of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 552-556.
[5] JIANG Mingting, HUANG Jing, ZHENG Shuping. Effects of Pin1 on Proliferation and Apoptosis of HepG2 Cells Under Endoplasmic Reticulum Stress[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 575-580.
[6] WANG Jue, JIN Zongrui, WANG Wei, YI Qilin, WANG Jilong, ZHU Hai, XU Banghao, GUO Ya, WEN Zhang. Prognostic Role of Immune-related Genes in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 599-605.
[7] XU Shasha, HAN Xingmin. Research Advances on Application of 18F-FDG PET/CT in Clinical Diagnosis and Treatment of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 384-389.
[8] CUI Honglei, ZHANG Xiaodan, GUO Danfeng, YAN Zhiping, GUO Wenzhi, ZHANG Shuijun. Expression of ENO3 and Its Effect on Sensitivity of Hepatocellular Carcinoma Cells to Oxaliplatin[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 438-443.
[9] ZHOU Yongjie, WANG Zhengfeng, YAN Jun, WANG Haiping, XU Wen, ZHOU Wence. Value of Preoperative Lactate Dehydrogenase-to-Albumin Ratio Combined with AFP in Evaluating Prognosis of Patients with Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 347-351.
[10] TAO Changcheng, ZHANG Kai, RONG Weiqi, WU Jianxiong. Research Progress of Early Recurrence and Cut-off Time of Hepatocellular Carcinoma after Radical Hepatectomy[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 359-363.
[11] ZHANG Haodong, WEI Fengxian, ZHANG Chunfang, XU Xiaodong. Clinical Value of Platelet and Its Parameters Combined with Tumor Markers in Preoperative Differentiation of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 213-218.
[12] CHEN Long, LIU Yujie, TIAN Suqing, WANG Cuiying, HE Donglei. Curative Effect of Lenvatinib Combined with Locoregional Therapy on PD-L1-positive Hepatocellular Carcinoma Patients with Type Ⅰ-Ⅲ Portal Vein Tumor Thrombus According to Cheng’s Classification[J]. Cancer Research on Prevention and Treatment, 2022, 49(01): 53-57.
[13] PANG Kangqing, MA Hongde, YANG Rulei, PANG Guohong. Expression and Clinical Significance of Serum PTX3 in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1078-1081.
[14] SONG Yanzhou, ZHANG Kun, CHEN Qijun, WEI Wenping, ZHAO Xin, LI Zhiwei, LI Wei. Experiment on Inhibiting NEK7 to Promote Apoptosis of Hepatocellular Carcinoma Cells[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 929-933.
[15] XU Gang, BU Shanshan, WANG Xiushen, GE Hong. Correlation Between cyclin G1 Expression and Efficacy of Radiotherapy on Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 958-962.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed